Olema Pharmaceuticals

Olema Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2007-01-01
Employees
74
Market Cap
$668.8M
Website
http://www.olema.com

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

First Posted Date
2023-08-30
Last Posted Date
2024-12-19
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
510
Registration Number
NCT06016738
Locations
🇬🇧

Clinical Trial Site, London, United Kingdom

🇲🇾

Clinical Trials Site, Sungai Petani, Kedah, Malaysia

Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus

First Posted Date
2022-08-19
Last Posted Date
2024-10-03
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
155
Registration Number
NCT05508906
Locations
🇺🇸

Advent Health Hematology and Oncology, Orlando, Florida, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 13 locations

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2022-03-04
Last Posted Date
2024-06-06
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT05266105
Locations
🇦🇺

Site 6101, Clayton, Victoria, Australia

🇦🇺

Site 6102, South Brisbane, Queensland, Australia

🇦🇺

Site 6109, Southport, Queensland, Australia

and more 5 locations

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

First Posted Date
2020-08-10
Last Posted Date
2023-08-22
Lead Sponsor
Olema Pharmaceuticals, Inc.
Target Recruit Count
153
Registration Number
NCT04505826
Locations
🇺🇸

University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇦🇺

Macquarie University, Sydney, New South Wales, Australia

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath